Nasdaq · Biotech stocks database

IVA — Inventiva S.A.

IVA (Inventiva S.A.) stock: $3.89, $919.0M market cap, $108.7M cash, $871.2M EV, $1.67B fully diluted market cap. Lead program: IVA337 (NASH - Nonalcoholic Steatohepatitis), Phase 3. Data from Fully Diluted's biotech stocks database.

What they do

We are a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of MASH. We have a wholly-owned research and development facility and a team with significant expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation.

Source: 20-F FY2025 via SEC EDGAR

Share price

$3.89

Market cap

$919.0M

Cash

$108.7M

Enterprise value

$871.2M

Balance sheet

Cash	$108.7M
Debt	$60.9M
Net cash	$47.8M
Enterprise value	$871.2M
Basic shares	236.3M shares
Fully diluted shares	429.8M shares
Fully diluted market cap	$1,671.9M
Cash per share	$0.46

Cash figures as of 2024-12-31. Database snapshot: 2026-11-10.

Share structure

Common

236.3M

Pre-funded warrants

61.7M

Options

22.1M

RSUs

6.9M

Warrants

96.1M

Converts

6.6M

Conv preferred

0.0M

ESPP reserve

0.0M

FDSO

429.8M

Cap table as of 2026-06-30.

Price history

Loading IVA daily closes…

Loading price history…

Next catalyst

lanifibranor · Est. Nov 15, 2026 · quarter midpoint · guided Now

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
GUIDEDEst. Nov 15, 2026 Now quarter midpoint	lanifibranor Phase 3 NATiV3 in MASH	Phase 3	MASH	Q4 2026
Nov 11 - Dec 23 in 12 mo	IVA337	Phase 3	NASH - Nonalcoholic Steatohepatitis	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Lead drug	IVA337
Lead indication	NASH - Nonalcoholic Steatohepatitis
Lead phase	Phase 3
Active trials	1
Collaborator trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT04849728	Phase 3	Active, not recruiting	Sponsor	Inventiva Pharma	—	NASH - Nonalcoholic Steatohepatitis	—
NCT05651724	Not disclosed	Recruiting	Collaborator	Julius Clinical	NVO	MASH; MASLD; MASH With Fibrosis	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for Inventiva Pharma on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
ADAR1 Capital Management	3,606,656	+1,432,258	0.64%	2026-08-14
Ikarian Capital	1,129,101	-300,000	0.68%	2026-08-14
BVF Partners	686,040	no change	0.07%	2026-08-14
Ally Bridge Group	634,800	-110,500	3.09%	2026-08-14
RTW Investments	0	-1,298,702	0.00%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Get the weekly biotech catalyst rundown.
Cash runways, financings, and trial readouts for all 718 stocks.

Subscribe to Compounding Ego

IVA — Inventiva S.A.

What they do

Balance sheet

Share structure

Price history

Next catalyst

Upcoming catalysts

Pipeline

Active clinical trials

Specialist fund holders

Latest news

IVA — Inventiva S.A. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Upcoming catalysts

Pipeline

Active clinical trials

Specialist fund holders

Latest news

IVA — Inventiva S.A.